NO20054868D0 - CaSr antagonist - Google Patents
CaSr antagonistInfo
- Publication number
- NO20054868D0 NO20054868D0 NO20054868A NO20054868A NO20054868D0 NO 20054868 D0 NO20054868 D0 NO 20054868D0 NO 20054868 A NO20054868 A NO 20054868A NO 20054868 A NO20054868 A NO 20054868A NO 20054868 D0 NO20054868 D0 NO 20054868D0
- Authority
- NO
- Norway
- Prior art keywords
- casr antagonist
- casr
- antagonist
- Prior art date
Links
- 101150027751 Casr gene Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Furan Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003119131 | 2003-04-23 | ||
| PCT/JP2004/005886 WO2004094362A1 (ja) | 2003-04-23 | 2004-04-23 | CaSRアンタゴニスト |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20054868D0 true NO20054868D0 (no) | 2005-10-21 |
| NO20054868L NO20054868L (no) | 2005-12-20 |
Family
ID=33308093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20054868A NO20054868L (no) | 2003-04-23 | 2005-10-21 | CaSr antagonist |
Country Status (30)
| Country | Link |
|---|---|
| US (4) | US7304174B2 (no) |
| EP (3) | EP2189439A3 (no) |
| JP (1) | JP3751312B2 (no) |
| KR (1) | KR100696927B1 (no) |
| CN (2) | CN101723921A (no) |
| AR (1) | AR044075A1 (no) |
| AT (1) | ATE452121T1 (no) |
| AU (1) | AU2004232604C1 (no) |
| BR (1) | BRPI0407097A (no) |
| CA (1) | CA2513738C (no) |
| CL (1) | CL2004000868A1 (no) |
| CO (1) | CO5640091A2 (no) |
| CY (1) | CY1109880T1 (no) |
| DE (1) | DE602004024668D1 (no) |
| DK (1) | DK1619180T3 (no) |
| ES (1) | ES2337576T3 (no) |
| HR (1) | HRP20100042T1 (no) |
| IL (1) | IL169575A (no) |
| MX (1) | MXPA05007609A (no) |
| MY (1) | MY138734A (no) |
| NO (1) | NO20054868L (no) |
| NZ (1) | NZ541188A (no) |
| PE (1) | PE20050460A1 (no) |
| PL (1) | PL1619180T3 (no) |
| PT (1) | PT1619180E (no) |
| RU (1) | RU2315036C2 (no) |
| SI (1) | SI1619180T1 (no) |
| TW (1) | TWI329628B (no) |
| WO (1) | WO2004094362A1 (no) |
| ZA (1) | ZA200505587B (no) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0302094D0 (en) | 2003-01-29 | 2003-02-26 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| WO2004106280A1 (ja) * | 2003-05-28 | 2004-12-09 | Japan Tobacco Inc. | CaSRアンタゴニスト |
| GB0324269D0 (en) | 2003-10-16 | 2003-11-19 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| US20070155819A1 (en) * | 2004-02-06 | 2007-07-05 | Marquis Robert W Jr | Calcilytic compounds |
| BRPI0710814A2 (pt) | 2006-04-20 | 2011-08-16 | Amgen Inc | formulações de emulsão estável |
| CA2681582C (en) | 2007-03-30 | 2015-07-14 | Amgen Inc. | Methods of treating bowel disorders |
| EP2292592B1 (en) * | 2008-06-05 | 2012-09-05 | Asahi Kasei Pharma Corporation | Sulfonamide compound and application thereof |
| RU2474572C1 (ru) | 2008-12-24 | 2013-02-10 | Дайити Санкио Компани, Лимитед | Инданильные соединения |
| CA2748249C (en) * | 2008-12-24 | 2013-07-02 | Daiichi Sankyo Company, Limited | Cyclic amine compounds |
| WO2010104882A1 (en) | 2009-03-10 | 2010-09-16 | Amgen Inc. | Methods of modulating sperm motility |
| WO2010103429A1 (en) * | 2009-03-10 | 2010-09-16 | Pfizer Inc. | 1,1-(Dimethyl-Ethylamino)-2-Hydroxy-Propoxy]-Ethyl}-3-Methyl-Biphenyl-4- Carboxylic Acid Derivatives As Calcium Receptor Antagonists |
| JP5250693B2 (ja) * | 2009-03-26 | 2013-07-31 | 日本たばこ産業株式会社 | カルボン酸化合物の製造方法 |
| WO2010113860A1 (ja) * | 2009-03-31 | 2010-10-07 | 第一三共株式会社 | ビフェニル-環状アミン化合物 |
| JP2012528086A (ja) | 2009-05-27 | 2012-11-12 | レオ ファーマ アクティーゼルスカブ | 新規のカルシウム感知受容体調節化合物およびその医薬用途 |
| EP2435400A2 (en) | 2009-05-27 | 2012-04-04 | Leo Pharma A/S | Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof |
| WO2012069420A2 (en) | 2010-11-26 | 2012-05-31 | Leo Pharma A/S | Calcium-sensing receptor-active compounds |
| US20130267516A1 (en) | 2010-11-26 | 2013-10-10 | Leo Pharma A/S | Substituted cyclopentyl-azines as casr-active compounds |
| RU2013128968A (ru) | 2010-11-26 | 2015-01-10 | Лео Фарма А/С | Соединения, активные в отношении кальций-чувствительного рецептора |
| US20130245084A1 (en) | 2010-11-26 | 2013-09-19 | Leo Pharma A/S | Calcium-sensing receptor-active compounds |
| GB201113538D0 (en) * | 2011-08-04 | 2011-09-21 | Karobio Ab | Novel estrogen receptor ligands |
| CN104583177B (zh) * | 2012-08-27 | 2016-09-07 | 卢平亚特兰蒂斯控股有限公司 | 作为钙敏感受体调节剂的芳基烷基胺化合物 |
| MX393292B (es) | 2016-06-13 | 2025-03-11 | Syneurx Int Taiwan Corp | Uso de benzoato de litio para tratar trastornos del sistema nervioso central |
| KR20220110789A (ko) * | 2019-12-09 | 2022-08-09 | 베이징 투오 지에 바이오파마수티컬 컴퍼니 리미티드 | 칼슘 감지 수용체 효능제 화합물 및 이의 응용 |
| US20220040112A1 (en) | 2020-08-04 | 2022-02-10 | Calcilytix Therapeutics, Inc. | Formulations of triphenyl calcilytic compounds |
| WO2022060987A1 (en) | 2020-09-18 | 2022-03-24 | Calcilytix Therapeutics, Inc. | Triphenyl calcilytic compounds for the treatment of autosomal dominant hypocalcemia type 1 (adh1) |
| TW202506101A (zh) | 2023-04-21 | 2025-02-16 | 美商柯西立提克斯療法有限公司 | 使用三苯基鈣敏感性化合物之副甲狀腺機能低下症治療 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE633760A (no) * | 1963-06-18 | |||
| DD207203A1 (de) * | 1982-06-21 | 1984-02-22 | Peter Meisel | Verfahren zur herstellung von epoxypropylethern |
| DE3743265A1 (de) * | 1987-12-19 | 1989-06-29 | Boehringer Ingelheim Kg | Neue ammoniumverbindungen, ihre herstellung und verwendung |
| US5276008A (en) * | 1990-08-09 | 1994-01-04 | Bayer Aktiengesellschaft | Substituted 4,5-diamino-1,2,4-triazol-3-(thi)ones |
| RU2147574C1 (ru) * | 1991-08-23 | 2000-04-20 | Эн-Пи-Эс Фармасьютикалз, Инк. | Арилалкиламины, композиции, способы лечения и диагностики, способы идентификации соединения |
| US6818660B2 (en) | 1996-04-09 | 2004-11-16 | Nps Pharmaceuticals, Inc. | Calcilytic compounds |
| WO1997037967A1 (en) * | 1996-04-09 | 1997-10-16 | Nps Pharmaceuticals, Inc. | Calcilytic compounds |
| ES2171839T3 (es) * | 1996-09-05 | 2002-09-16 | Lilly Co Eli | Analogos de carbazol como agonistas adrenergicos selectivos de beta3. |
| UY24949A1 (es) | 1997-04-08 | 2001-04-30 | Smithkline Beecham Corp | Compuestos calcilíticos |
| AR018177A1 (es) | 1998-04-08 | 2001-10-31 | Smithkline Beecham Corp | Compuestos calciliticos, una composicion farmaceutica que los comprende y el uso de los mismos para la manufactura de un medicamento. |
| AR014975A1 (es) | 1998-04-08 | 2001-04-11 | Nps Pharma Inc | Compuestos calciliticos, una composicion farmaceutica que los comprende, y el uso de los mismos para la fabricacion de un medicamento |
| US20020052509A1 (en) | 1998-04-08 | 2002-05-02 | Smithkline Beecham Corporation | Calcilytic compounds and method of use |
| US6334338B1 (en) * | 1998-07-02 | 2002-01-01 | Lucent Technologies Inc. | Sol gel process of making a fiber preform with removal of oxide particles |
| US6335338B1 (en) | 1998-08-12 | 2002-01-01 | Smithkline Beecham Corporation | Calcilytic compounds |
| JP2002522499A (ja) | 1998-08-12 | 2002-07-23 | スミスクライン・ビーチャム・コーポレイション | カルシウム分解化合物 |
| ATE277931T1 (de) * | 1998-10-23 | 2004-10-15 | Hoffmann La Roche | Bicyclische stickstoffheteroaryl verbindungen |
| PE20001456A1 (es) | 1999-02-02 | 2001-01-28 | Smithkline Beecham Corp | Compuestos calcioliticos |
| JP2003508586A (ja) * | 1999-08-27 | 2003-03-04 | ザ、プロクター、エンド、ギャンブル、カンパニー | 迅速に作用する処方成分、それらの成分を使用する組成物および洗濯方法 |
| IL152925A (en) | 1999-10-21 | 2010-04-15 | Pfizer | Pharmaceutical preparations for the treatment of neurological disease containing an inhibitor of ring guanizine '3', 5 '- monophosphate phosphodiesterase 5 and one of gabapentin or pregabalin |
| AR030684A1 (es) | 2000-01-24 | 2003-09-03 | Smithkline Beecham Corp | Compuestos calciliticos, uso de dichos compuestos en la manufactura de medicamentos, e intermediarios utiles en la preparacion de dichos compuestos |
| US20030018203A1 (en) * | 2002-07-17 | 2003-01-23 | Largo Maria Amparo | Calcilytic compounds |
| US6867299B2 (en) * | 2000-02-24 | 2005-03-15 | Hoffmann-La Roche Inc. | Oxamide IMPDH inhibitors |
| AU7692301A (en) | 2000-07-21 | 2002-02-05 | Smithkline Beecham Corp | Calcilytic compounds |
| WO2002014259A1 (en) | 2000-08-11 | 2002-02-21 | Japan Tobacco Inc. | Calcium receptor antagonists |
| DE60124148T2 (de) | 2000-10-25 | 2007-09-06 | Smithkline Beecham Corp. | Kalzilytische verbindungen |
| JP2004519428A (ja) | 2000-10-25 | 2004-07-02 | スミスクライン・ビーチャム・コーポレイション | カルシライティック化合物 |
| AR038658A1 (es) * | 2001-06-15 | 2005-01-26 | Novartis Ag | Derivados de 4-aril-2(1h) quinazolinona y 4-aril-quinazolina 2-sustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de un medicamento |
| US6864267B2 (en) | 2001-07-16 | 2005-03-08 | Smithkline Beecham Corporation | Calcilytic compounds |
| WO2004106280A1 (ja) | 2003-05-28 | 2004-12-09 | Japan Tobacco Inc. | CaSRアンタゴニスト |
-
2004
- 2004-04-23 AT AT04729243T patent/ATE452121T1/de active
- 2004-04-23 RU RU2005123985/04A patent/RU2315036C2/ru not_active IP Right Cessation
- 2004-04-23 PE PE2004000403A patent/PE20050460A1/es not_active Application Discontinuation
- 2004-04-23 DK DK04729243.8T patent/DK1619180T3/da active
- 2004-04-23 CA CA2513738A patent/CA2513738C/en not_active Expired - Fee Related
- 2004-04-23 AU AU2004232604A patent/AU2004232604C1/en not_active Ceased
- 2004-04-23 PL PL04729243T patent/PL1619180T3/pl unknown
- 2004-04-23 ZA ZA200505587A patent/ZA200505587B/en unknown
- 2004-04-23 PT PT04729243T patent/PT1619180E/pt unknown
- 2004-04-23 KR KR1020057013977A patent/KR100696927B1/ko not_active Expired - Fee Related
- 2004-04-23 US US10/830,480 patent/US7304174B2/en not_active Expired - Lifetime
- 2004-04-23 MX MXPA05007609A patent/MXPA05007609A/es active IP Right Grant
- 2004-04-23 CN CN200910253477A patent/CN101723921A/zh active Pending
- 2004-04-23 BR BR0407097-6A patent/BRPI0407097A/pt not_active IP Right Cessation
- 2004-04-23 MY MYPI20041512A patent/MY138734A/en unknown
- 2004-04-23 EP EP09177717A patent/EP2189439A3/en not_active Withdrawn
- 2004-04-23 EP EP04729243A patent/EP1619180B1/en not_active Expired - Lifetime
- 2004-04-23 DE DE602004024668T patent/DE602004024668D1/de not_active Expired - Lifetime
- 2004-04-23 HR HR20100042T patent/HRP20100042T1/hr unknown
- 2004-04-23 ES ES04729243T patent/ES2337576T3/es not_active Expired - Lifetime
- 2004-04-23 JP JP2005505801A patent/JP3751312B2/ja not_active Expired - Lifetime
- 2004-04-23 CL CL200400868A patent/CL2004000868A1/es unknown
- 2004-04-23 WO PCT/JP2004/005886 patent/WO2004094362A1/ja not_active Ceased
- 2004-04-23 NZ NZ541188A patent/NZ541188A/en not_active IP Right Cessation
- 2004-04-23 CN CN200480002843A patent/CN100577633C/zh not_active Expired - Fee Related
- 2004-04-23 SI SI200431348T patent/SI1619180T1/sl unknown
- 2004-04-23 AR ARP040101388A patent/AR044075A1/es unknown
- 2004-04-23 EP EP10179435.2A patent/EP2308828A3/en not_active Withdrawn
- 2004-04-23 TW TW093111360A patent/TWI329628B/zh not_active IP Right Cessation
-
2005
- 2005-07-07 IL IL169575A patent/IL169575A/en not_active IP Right Cessation
- 2005-10-19 CO CO05106148A patent/CO5640091A2/es active IP Right Grant
- 2005-10-21 NO NO20054868A patent/NO20054868L/no not_active Application Discontinuation
-
2007
- 2007-08-17 US US11/840,739 patent/US20080255042A1/en not_active Abandoned
-
2009
- 2009-03-27 US US12/412,964 patent/US20090326058A1/en not_active Abandoned
-
2010
- 2010-03-10 CY CY20101100234T patent/CY1109880T1/el unknown
-
2011
- 2011-12-23 US US13/336,205 patent/US20120301552A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE452121T1 (de) | Casr-antagonist | |
| ATE363383T1 (de) | Schlingenware | |
| DE50300325D1 (de) | Vaginalpflegezusammensetzung | |
| DE502004001683D1 (de) | Kabelführung | |
| DE602004031845D1 (de) | Ng | |
| DE602004001197D1 (de) | Umverpackungsschrumpffolie | |
| AT502792A5 (de) | Düsenanpressvorrichtung | |
| DE112004000620D2 (de) | Struktoguss | |
| DE10355350A8 (de) | Elektromodul | |
| DE502004000672D1 (de) | Pigmentpreparationen | |
| DE502004001524D1 (de) | Hydrolager | |
| ATA662003A (de) | Trink-mundstück | |
| ATE446959T1 (de) | Chromenonindole | |
| DE602004018799D1 (de) | Ng | |
| DE502004002978D1 (de) | N-biarylamide | |
| DE502004001629D1 (de) | Bremsenprüfstand | |
| ATE444953T1 (de) | Substituierte spirobenzazepine | |
| DE502004003122D1 (de) | Hydrolager | |
| DE502004000518D1 (de) | Mitgängergabelhubwagen | |
| DE502004005162D1 (de) | Leistungsregelvorricthung | |
| DE10394329D2 (de) | Mäanderstent | |
| ATE406350T1 (de) | Prolinylarylacetamide | |
| DE10329218B4 (de) | Hotflue | |
| DE502004002771D1 (de) | Umlenkhebel | |
| DE502004002619D1 (de) | Flaschenverschluss |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |